<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        323-212-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HEPAVIR 0.5 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENTECAVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1502.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AF10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Hepavir is an anti-viral medicine, used to treat chronic (long term) hepatitis B virus (HBV)<br />infection in adults. Hepavir can be used in people whose liver is damaged but still functions<br />properly (compensated liver disease) and in people whose liver is damaged and does not function<br />properly (decompensated liver disease).<br />Hepavir tablets are also used to treat chronic (long term) HBV infection in children and<br />adolescents aged 2 years to less than 18 years. Hepavir can be used in children whose liver is<br />damaged but still functions properly (compensated liver disease).<br />Infection by the hepatitis B virus can lead to damage to the liver. Hepavir reduces the amount of<br />virus in your body and improves the condition of the liver.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Hepavir</strong><br />&bull; If you are allergic (hypersensitive) to entecavir or any of the other ingredients of this<br />medicine (listed in section 6).</p><p><strong>Warning and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Hepavir<br />▪ If you have ever had problems with your kidneys, tell your doctor. This is important<br />because Hepavir is eliminated from your body through the kidneys and your dose or<br />dosing schedule may need to be adjusted.<br />▪ Do not stop taking Hepavir without your doctor&rsquo;s advice since your hepatitis may<br />worsen after stopping treatment. When your treatment with Hepavir is stopped, your<br />doctor will continue to monitor you and take blood tests for several months.<br />▪ Discuss with your doctor whether your liver functions properly and, if not, what the<br />possible effects on your Hepavir treatment may be.<br />▪ If you are also infected with HIV (human immunodeficiency virus) be sure to tell your<br />doctor. You should not take Hepavir to treat your hepatitis B infection unless you are<br />taking medicines for HIV at the same time, as the effectiveness of future HIV treatment<br />may be reduced. Hepavir will not control your HIV infection.<br />▪ Taking Hepavir will not stop you from infecting other people with hepatitis B virus<br />(HBV) through sexual contact or body fluids (including blood contamination). So, it is<br />important to take appropriate precautions to prevent others from becoming infected with<br />HBV. A vaccine is available to protect those at risk from becoming infected with HBV.<br />▪ Hepavir belongs to a class of medicines that can cause lactic acidosis (excess of lactic<br />acid in your blood) and enlargement of the liver. Symptoms such as nausea, vomiting and<br />stomach pain might indicate the development of lactic acidosis. This rare but serious side<br />effect has occasionally been fatal. Lactic acidosis occurs more often in women,<br />particularly if they are very overweight. Your doctor will monitor you regularly while<br />you are receiving Hepavir.</p><p>▪ If you have previously received treatment for chronic hepatitis B, please inform your<br />doctor.<br />Children and adolescents<br />Hepavir should not be used for children below 2 years of age or weighing less than 10 kg.<br />Other medicines and Hepavir<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other<br />medicines, including medicines obtained without a prescription.</p><p>Taking Hepavir with food and drink<br />In most cases you may take Hepavir with or without food. However, if you have had a previous<br />treatment with a medicine containing the active substance lamivudine you should consider the<br />following. If you were switched over to Hepavir because the treatment with lamivudine was not<br />successful, you should take Hepavir on an empty stomach once daily. If your liver disease is very<br />advanced, your doctor will also instruct you to take Hepavir on an empty stomach. Empty<br />stomach means at least 2 hours after a meal or at least 2 hours before your next meal.<br />Hepavir 0.5mg: Children and adolescents (from 2 to less than 18 years of age) can take Hepavir<br />with or without food.<br />Pregnancy and breastfeeding<br />Tell your doctor if you are pregnant or planning to become pregnant. It has not been<br />demonstrated that Hepavir is safe to use during pregnancy. Hepavir must not be used during<br />pregnancy unless specifically directed by your doctor. It is important that women of childbearing<br />age receiving treatment with Hepavir use an effective method of contraception to avoid<br />becoming pregnant.<br />You should not breast-feed during treatment with Hepavir. Tell your doctor if you are<br />breastfeeding. It is not known whether entecavir, the active ingredient in Hepavir, is excreted in<br />human breast milk.<br />Driving and using machines<br />Dizziness, tiredness (fatigue) and sleepiness (somnolence) are common side effects which may<br />impair your ability to drive and use machines. If you have any concerns consult your doctor.<br />Hepavir contains lactose<br />This medicinal product contains lactose. If you have been told by your doctor that you have an<br />intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Not all patients need to take the same dose of Hepavir.<br />Always take Hepavir exactly as your doctor has told you. You should check with your doctor or<br />pharmacist if you are not sure. The usual dose is either 0.5 or 1 mg once daily orally.<br />For adults the recommended dose is either 0.5 mg or 1 mg once daily orally (by mouth).<br />Your dose will depend on:<br />▪ Whether you have been treated for HBV infection before, and what medicine you received.<br />▪ Whether you have kidney problems. Your doctor may prescribe a lower dose for you or<br />instruct you to take it less often than once a day.<br />▪ The condition of your liver.</p><p>For children and adolescents (from 2 to less than 18 years of age), your child&#39;s doctor will<br />decide the right dose based on your child&#39;s weight. The Entecavir oral solution is recommended<br />for patients weighing from 10 kg to 32.5 kg. Children weighing at least 32.6 kg may take the oral<br />solution or the 0.5 mg tablet. All dosing will be taken once daily orally (by mouth). There are no<br />recommendations for Hepavir in children less than 2 years of age or weighing less than 10 kg.<br />Your doctor will advise you on the dose that is right for you. Always take the dose recommended<br />by your doctor to ensure that your medicine is fully effective and to reduce the development of<br />resistance to treatment. Take Hepavir as long as your doctor has told you. Your doctor will tell<br />you if and when you should stop the treatment.<br />Some patients must take Hepavir on an empty stomach (see Hepavir with food and drink in<br />Section 2). If your doctor instructs you to take Hepavir on an empty stomach, empty stomach<br />means at least 2 hours after a meal and at least 2 hours before your next meal.<br />If you take more Hepavir than you should<br />Contact your doctor at once.<br />If you forget to take Hepavir<br />It is important that you do not miss any doses. If you miss a dose of Hepavir, take it as soon as<br />possible, and then take your next scheduled dose at its regular time. If it is almost time for your<br />next dose, do not take the missed dose. Wait and take the next dose at the regular time. Do not<br />take a double dose to make up for a forgotten dose.<br />Do not stop Hepavir without your doctor&rsquo;s advice<br />Some people get very serious hepatitis symptoms when they stop taking Hepavir. Tell your<br />doctor immediately about any changes in symptoms that you notice after stopping treatment.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Hepavir can cause side effects, although not everybody gets them.<br />Patients treated with Hepavir have reported the following side effects:<br />Adults:<br />&bull; Common (at least 1 in 100 patients): headache, insomnia (inability to sleep), fatigue (extreme<br />tiredness), dizziness, somnolence (sleepiness), vomiting, diarrhoea, nausea, dyspepsia<br />(indigestion), and increased blood levels of liver enzymes.<br />&bull; Uncommon (at least 1 in 1,000 patients): rash, hair loss.<br />&bull; Rare (at least 1 in 10,000 patients): severe allergic reaction.</p><p>Children and adolescents<br />The side effects experienced in children and adolescents are similar to those experienced in<br />adults as described above with the following difference:<br />Very common (at least 1 in 10 patients): low levels of neutrophils (one type of white blood cells,<br />which are important in fighting infection).<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side<br />effects not listed in this leaflet.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible<br />side effects not listed in this leaflet. You can also report side effects directly via The National<br />Pharmacovigilance and Drug Safety Centre (NPC). By reporting side affects you can help<br />provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the blister or carton after<br />EXP. That expiry date refers to the last day of that month.<br />&bull; Do not store above 30&deg;C.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />&bull; The active substance is entecavir. Each film-coated tablet contains 0.5mg or 1 mg Entecavir<br />Monohydrate.<br />&bull; The other ingredients are:<br />Tablet core: Lactose, avicel, crosvidone, povidone, magnesium stearate.<br />Tablet coating: Opadry pink, purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Hepavir 0.5mg: A pink to light pink, square, film-coated tablet, engraved with “30” on one side
and plain on the other sides.
Hepavir 1mg: A pink to light pink, oblong, biconvex film-coated tablet, engraved with “31” on
one side and plain on the other sides.
Hepavir film-coated tablets are supplied in cartons containing 30 film-coated tablets.
Hepavir 0.5 mg containing 15 film-coated tablets per blister.
Hepavir 1 mg containing 10 film-coated tablets per blister.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer<br />SPIMACO<br />Al-Qassim pharmaceutical plant<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>هيبافير هو دواء مضاد للفيروسات، يستخدم في علاج الحالات المزمنة )طويلة الأمد( من الإصابة بالالتهاب الكبدي<br />عند البالغين. يكمن استخدام هيبافير لمرضى الالتهاب الكبدي سواء أصيبوا بتلف بالكبد وما زال الكبد يعمل B الفيروسي نوع<br />عندهم بشكل جيد )مرض الكبد المعوض(، أم حدث عندهم تلف بالكبد أدى إلى أن يفقد الكبد قدرته على العمل بشكل جيد<br />)مرض الكبد الغير معوض(.<br />لدى B تستخدم أقراص هيبافير أيضًا في علاج الحالات المزمنة )طويلة الأمد( من الإصابة بالالتهاب الكبدي الفيروسي نوع<br />الأطفال والمراهقين الذين تتراوح أعمارهم بين عامين إلى أقل من 18 عامًا. يمكن استخدام هيبافير في الأطفال الذين يعانون<br />من تلف الكبد، ولكنه لا يزال يعمل بشكل جيد )مرض الكبد المعوض(.<br />تؤدي إلى حدوث تلف بالكبد. يقوم هيبافير بتقليل وجود هذا الفيروس B إن الإصابة بمرض الالتهاب الكبدي الفيروسي نوع<br />بجسمك، مما يحسن حالة الكبد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>امتنع عن تناول هيبافير فى الحالات الآتية :</strong><br />.) &bull; إذا كنت تعاني من فرط التحسس )التأق( من إنتيكافير أو لأي من لمكونات الأخرى لهذا الدواء )المذكورة في الفقرة 6<br /><strong>المحاذير والاحتياطات&nbsp;</strong></p><p>تحدث إلي الطبيب أو الصيدلي قبل تناول هيبافير<br />إذا كنت تعاني من أي مشاكل في كليتيك، أخبر طبيبك. تكمن أهمية ذلك في أن عملية التخلص من هيبافير تحدث في ▪<br />جسمك عن طريق كليتيك لذا ففي حالة وجود مشكلة ما في الكلية فإن ذلك قد يتطلب تعديل الجرعة أو جدول الجرعات<br />عندك.<br />لا تتوقف عن تناول هيبافير بدون موافقة طبيبك إذ أن ذلك قد يؤدي إلى ازدياد حالتك سوءا. عندما يقوم الطبيب بإيقاف ▪<br />العلاج ب هيبافير فإنه سيستمر بإجراء فحوصات للدم لعدة أشهر بعد ذلك.<br />استشر طبيبك فيما إذا كان الكبد يعمل عندك بشكل جيد فإذا كان لا يعمل بشكل جيد، عندها اسأله عن الأعراض الجانبية ▪<br />المحتملة من تناول هيبافير في حالتك.<br />إذا كنت مصابا بمرض نقص المناعة المكتسبة )الإيدز( فضلا أخبر طبيبك بذلك. عليك عدم تناول هيبافير لعلاج مرض ▪<br />ما لم تكن تتناول علاج للإيدز في نفس الوقت، حيث إن تناول هيبافير لوحده في مرضى الإيدز سيؤدي B الالتهاب الكبدي<br />إلى تقليل كفاءة أي علاج سوف يتم استخدامه لعلاج الإيدز لديك. كما أن هيبافير لا يعالج الإيدز.<br />للأخرين عن طريق الاتصال B إن تناولك ل هيبافير لا يمنع إمكانية نقلك عدوى الإصابة بمرض التهاب الكبد الفيروسي ▪<br />الجنسي أو سوائل الجسم )بما في ذلك الدم الملوث(. لذا من المهم أخذ التدابير الوقائية التي تمنع نقلك العدوى للأخرين. كما<br />أن هناك لقاحات متوافرة لتحمي هؤلاء الأكثر عرضة للإصابة بمرض الالتهاب الكبدي الفيروسي.<br />ينتمي هيبافير لمجموعة من الأدوية التي قد تتسبب في حدوث التحمض اللبني )زيادة مستوى حمض اللبن في جسمك( ▪<br />وتضخم الكبد، يدل على حدوث التحمض اللبني ظهور أعراض جانبية مثل الغثيان، القيء، وألم المعدة. هذه المشكلة نادرة<br />الحدوث لكنها في نفس الوقت قد تكون أحيانا مميتة. احتمالية ظهور التحمض اللبني تكون عند النساء بشكل أكبر خصوصا<br />إذا كن يعانين من وزن زائد. إن طبيبك سوف يقوم بمراقبتك يشكل دوري أثناء العلاج ب هيبافير.<br />المزمن. B فضلا أخبر طبيبك المعالج إذا كنت في السابق قد تلقيت علاجا لالتهاب الكبد الفيروسي ▪<br /><strong>الأطفال والمراهقون</strong><br />لا ينبغي استخدام هيبافير للأطفال الذين تقل أعمارهم عن عامين أو وزنهم أقل من 10 كجم.<br /><strong>الأدوية الأخرى وهيبافير</strong><br />فضلا يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت في الآونة الأخيرة أي أدوية أخرى وذلك يشمل الأدوية التى<br />قد حصلت عليها بدون وصفة طبية.</p><p>تناول هيبافير مع الطعام والشراب<br />في معظم الحالات يمكنك تناول هيبافير مع الطعام أو بدونه. بالرغم من ذلك فإنه إذا كنت في السابق تتناول دواء يحتوي على<br />المادة الفعالة لاميفودين ثم قام الطبيب بتغير علاجك إلى هيبافير لأن لاميفودين لم يكن فعالا، عندها يجب عليك تناول هيبافير<br />على معدة فارغة مرة واحدة يوميا. كذلك الحال في حالة أن يكون مرض الالتهاب الكبدي متقدما جدا عندها سيخبرك الطبيب<br />بأنه يتوجب عليك تناول هيبافير على معدة فارغة. المعدة الفارغة تعني على الأقل ساعتين قبل أو بعد الوجبة التي تتناولها.<br />هيبافير 0.5 ملجم: يمكن للأطفال والمراهقين )من 2 إلى أقل من 18 عامًا( تناول هيبافير مع أو بدون طعام.</p><p><strong>الحمل والرضاعة</strong><br />أخبري طبيبك إذا كنت حاملا أو تخططين للحمل. حيث إنه لم تتم دراسة أمان تناول هيبافير أثناء الحمل. لذا يتوجب عدم تناول<br />هيبافير أثناء الحمل ما لم يوص الطبيب بغير ذلك. من المهم جدا للنساء في الأعمار القادرة على الإنجاب اتخاذ وسيلة فعالة<br />لمنع حدوث الحمل عند تناول هيبافير.<br />كما يتوجب عليك عدم إرضاع طفلك رضاعة طبيعية أثناء تناول هيبافير. لذا أخبري طبيبك قبل تناول هيبافير إذا كنت<br />ترضعين طفلك رضاعة طبيعية فمن غير المعروف فيما إذا كانت المادة الفعالة في هيبافير: إنتيكافير يتم إفرازها في حليب الأم.<br /><strong>القيادة واستخدام الآلات</strong><br />إن الدوخة، التعب )الإرهاق( والنعاس من الأعراض الجانبية الشائعة المحتملة والتي قد تؤدي إلى التأثير في قدرتك على القيادة<br />واستخدام الآلات. إذا كان لديك أي مخاوف فضلا أخبر طبيبك.<br />هيبافير يحتوي على اللاكتوز<br />يحتوي هذا الدواء على لاكتوز. إذا تم إخبارك من قبل الطبيب بأنك لا تستطيع تحمل بعض أنواع السكريات، تواصل مع طبيبك<br />قبل تناول هذا الدواء .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا يحتاج كل المرضى إلى تناول نفس الجرعة من هيبافير.<br />قم بتناول هيبافير تماما كما اخبرك طبيبك. إذا كنت غير واثق يجب عليك التحقق مع طبيبك أو الصيدلي. الجرعة الاعتيادية هي<br />0.5 أو 1 ملجم مرة واحدة يوميا عن طريق الفم .<br />جرعتك تعتمد على:<br />إذا كان قد تم علاجك من الالتهاب الكبدي الفيروسي سابقا، وما هي الأدوية التي تناولتها. ▪<br />إذا كنت تعاني من مشاكل في الكلى. إذ قد يقوم طبيبك بوصف جرعة أقل أو قد يطلب منك تناول الدواء بتكرار اقل من ▪<br />مرة واحدة يوميا.<br />حالة الكبد لديك . ▪<br />بالنسبة للأطفال والمراهقين )من 2 إلى أقل من 18 عامًا(، سيقرر طبيب طفلك الجرعة المناسبة بناءً على وزن طفلك. يوصى<br />باستخدام محلول إنتيكافير عن طريق الفم للمرضى الذين يزنون من 10 كجم إلى 32.5 كجم. يمكن للأطفال الذين يزنون 32.6<br />كجم على الأقل تناول المحلول الفموي أو قرص 0.5 ملجم. يتم تناول جميع الجرعات مرة واحدة يوميا عن طريق الفم. لا<br />ينصح باستخدام هيبافير في الأطفال الذين تقل أعمارهم عن سنتين أو يزنون أقل من 10 كجم.<br />سيقوم طبيبك بوصف الجرعة المناسبة لحالتك. احرص دائما على تناول الجرعة الموصي بها من قبل الطبيب لضمان الحصول<br />على الفعالية المطلوبة ولتقليل خطورة احتمالية تطور مقاومة للدواء من قبل الفيروس. تناول هيبافير طالما اخبرك الطبيب<br />بذلك. كما انه سيخبرك متى وكيف تتوقف عن تناول هذا الدواء .<br />يجب على بعض المرضى تناول هيبافير على معدة فارغة )انظر هيبافير مع الطعام والشراب في القسم 2(. إذا أمرك طبيبك<br />بتناول هيبافير على معدة فارغة، فإن المعدة الفارغة تعني ساعتين على الأقل بعد الوجبة وقبل ساعتين على الأقل من الوجبة<br />التالية .</p><p>إذا تناولت هيبافير أكثر مما يجب<br />اتصل بطبيبك فورا.<br />إذا نسيت تناول جرعة من هيبا فير<br />من المهم ان لا تنسى أي جرعة. في حالة نسيانك لتناول جرعة تناولها فور تذكر ذلك. بعد ذلك تناول الجرعة التالية حسب<br />البرنامج وفي وقتها. إذا كان الوقت قريبا جدا من الجرعة التالية، لا تتناول الجرعة التي نسيتها انتظر وتناول الجرعة التالية في<br />وقتها. لا تتناول جرعة مزدوجة لتعويض الجرعة التي نسيتها.<br />لا تتوقف عن تناول هيبافير بدون موافقة الطبيب<br />قد تزداد حالة الالتهاب الكبدي سوءا عند بعض المرضى إذا توقفوا عن تناول هيبافير. أخبر طبيبك فورا إذا لاحظت حدوث أي<br />تغير في الأعراض عندك بعد التوقف عن هيبافير.<br />إذا كانت لديك مزيد من الأسئلة حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية هيبافير قد يسبب أعراض جانبية، رغم أنها لا تصيب الجميع. قد تحدث الأعراض الجانبية الآتية مع تناول<br />هيبافير.<br />أبلغ المرضى الذين عولجوا باستخدام هيبافير عن الأعراض الجانبية التالية:<br />البالغين:<br />&bull; أعراض جانبية شائعة الحدوث )تصيب على الأقل 1 من كل 100 مريض(: صداع، أرق )عدم القدرة على النوم(، إرهاق<br />)إعياء شديد(، دوخة، نعاس، قيء، إسهال، غثيان، عسر هضم، ارتفاع مستوى إنزيمات الكبد في الدم .<br />&bull; أعراض جانبية غير شائعة الحدوث )تصيب على الأقل 1 من كل 1000 مريض(: الطفح، تساقط الشعر.<br />&bull; أعراض جانبية نادرة الحدوث )تصيب على الأقل 1 من كل 10000 مريض(: تفاعلات فرط تحسس شديدة.<br />الأطفال والمراهقون<br />الأعراض الجانبية التي يعاني منها الأطفال والمراهقون مماثلة لتلك التي يعاني منها البالغون ك ما هو موضح أعلاه مع<br />الاختلاف التالي:<br />أعراض جانبية شائعة جدًا )تصيب 1 على الأقل من كل 10 مرضى(: انخفاض مستويات العدلات )نوع واحد من خلايا الدم<br />البيضاء، وهو مهم في مكافحة العدوى(.<br />إذا ظهرت عليك أي أعراض جانبية، فتحدث مع طبيبك أو الصيدلي. يشمل ذلك أي أعراض جانبية محتملة غير المذكورة في<br />هذه النشرة.<br />الإبلاغ عن الأعراض الجانبية<br />إذا ظهرت عليك أي أعراض جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض جانبية محتملة<br />غير المُدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عبر المركز الوطني للتيقظ والسلامة الدوائية.<br />يمكنك من خلال الإبلاغ عن الأعراض الجانبية أن تساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيدا عن متناول ونظر الأطفال.<br />تاريخ الانتهاء يشير إلى اليوم .EXP &bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الشريط والعبوة بعد<br />الأخير من كل شهر.<br />&bull; لا يحفظ في درجة حرارة أعلي من 30 درجة مئوية.<br />&bull; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من<br />الأدوية التي لم تعد تستخدم. وسوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هى إنتيكافير. يحتوي كل قرص على 0.5 أو 1 ملجم إنتيكافير على هيئة إنتيكافير أحادي التموه.<br />&bull; المكونات الأخرى هي:<br />داخل القرص: لاكتوز، افيسيل، كروسفيدون، بوفيدون، ستياريت المغنيسيوم.<br />القشرة الرقيقة: أوبادري وردي، ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>هيبافير 0.5 ملجم: أقراص مغلفة بطبقة رقيقة ذات لون يتراوح بين الوردي والوردي الفاتح ذات شكل مربع، محفورة برقم<br />30 &quot; على احدى الجوانب وجلية السطح على الجانب الاخر . &quot;<br />هيبافير 1 ملجم: أقراص مغلفة بطبقة رقيقة ذات لون يتراوح بين الوردي والوردي الفاتح ذات شكل مستطيل، ثنائية التحدب،<br />محفورة برقم &quot; 31 &quot; على احدى الجوانب وجلية السطح على الجانب الاخر.<br />يتوفر هيبافير على هيئة أقراص مغلفة بطبقة رقيقة في عبوات تحتوي على 30 قرص مغلف بطبقة رقيقة.<br />يحتوي كل شريط من هيبافير 0.5 ملجم على 15 قرص مغلف بطبقة رقيقة.<br />يحتوي كل شريط من هيبافير 1 ملجم على 10 أقراص مغلفة بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك الحقوق التسويقية والمصنع<br />الدوائية<br />مصنع الأدوية بالقصيم<br />المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابريل 2021 .                          
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hepavir 0.5 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 0.5 mg entecavir (as monohydrate).
Excipients: each tablet contains 120.5 mg lactose.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
A pink to light pink, square, film-coated tablet, engraved with “30” on one side and plain on
the other sides.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hepavir is indicated for the treatment of chronic hepatitis B virus (HBV) infection (see<br />section 5.1) in adults with:<br />&bull; Compensated liver disease and evidence of active viral replication, persistently<br />elevated serum alanine aminotransferase (ALT) levels and histological evidence<br />of active inflammation and/or fibrosis.<br />&bull; Decompensated liver disease (see section 4.4).<br />For both compensated and decompensated liver disease, this indication is based on<br />clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg<br />negative HBV infection. With respect to patients with lamivudine-refractory hepatitis<br />B, see sections 4.4 and 5.1.<br />Hepavir is also indicated for the treatment of chronic HBV infection in nucleoside naive<br />paediatric patients from 2 to &lt; 18 years of age with compensated liver disease who have<br />evidence of active viral replication and persistently elevated serum ALT levels, or<br />histological evidence of moderate to severe inflammation and/or fibrosis. With respect<br />to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Therapy should be initiated by a physician experienced in the management of chronic<br />hepatitis B infection.</p><p><u>Posology</u></p><p><em>Compensated liver disease<br />Nucleoside na&iuml;ve patients: the recommended dose is 0.5 mg once daily, with or without<br />food.<br />Lamivudine-refractory patients (i.e. with evidence of viraemia while on lamivudine or<br />the presence of lamivudine resistance [LVDr] mutations) (see sections 4.4 and 5.1): the<br />recommended dose is 1 mg once daily, which must be taken on an empty stomach<br />(more than 2 hours before or more than 2 hours after a meal) (see section 5.2).<br />Decompensated liver disease<br />The recommended dose for patients with decompensated liver disease is 1 mg once<br />daily, which must be taken on an empty stomach (more than 2 hours before or more<br />than 2 hours after a meal) (see section 5.2). For patients with lamivudine-refractory<br />hepatitis B, see sections 4.4 and 5.1.<br />Duration of therapy<br />The optimal duration of treatment is unknown. Treatment discontinuation may be<br />considered as follows:<br />&bull; In HBeAg positive patients, treatment should be administered at least until HBe<br />seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection on two<br />consecutive serum samples at least 3-6 months apart) or until HBs seroconversion or<br />there is loss of efficacy (see section 4.4).<br />&bull; In HBeAg negative patients, treatment should be administered at least until HBs<br />seroconversion or there is evidence of loss of efficacy. With prolonged treatment for<br />more than 2 years, regular reassessment is recommended to confirm that continuing the<br />selected therapy remains appropriate for the patient.<br />In patients with decompensated liver disease or cirrhosis, treatment cessation is not<br />recommended.</em></p><p><em>Paediatric population<br />For appropriate dosing in the paediatric population, Hepavir oral solution or Hepavir<br />0.5 mg film-coated tablets are available.<br />The decision to treat paediatric patients should be based on careful consideration of<br />individual patient needs and with reference to current paediatric treatment guidelines</em></p><p><em>including the value of baseline histological information. The benefits of long-term<br />virologic suppression with continued therapy must be weighed against the risk of<br />prolonged treatment, including the emergence of resistant hepatitis B virus.<br />Serum ALT should be persistently elevated for at least 6 months prior to treatment of<br />paediatric patients with compensated liver disease due to HBeAg positive chronic<br />hepatitis B; and for at least 12 months in patients with HBeAg negative disease.<br />Paediatric patients with body weight of at least 32.6 kg, should be administered a daily<br />dose of one 0.5 mg tablet or 10 ml (0.5 mg) of the oral solution, with or without food.<br />The oral solution should be used for patients with body weight less than 32.6 kg.<br />Duration of therapy for paediatric patients<br />The optimal duration of treatment is unknown. In accordance with current paediatric<br />practice guidelines, treatment discontinuation may be considered as follows:<br />▪ In HBeAg positive paediatric patients, treatment should be administered for at least 12<br />months after achieving undetectable HBV DNA and HBeAg seroconversion (HBeAg<br />loss and anti-HBe detection on two consecutive serum samples at least 3-6 months<br />apart) or until HBs seroconversion or there is loss of efficacy. Serum ALT and HBV<br />DNA levels should be followed regularly after treatment discontinuation (see section<br />4.4).<br />▪ In HBeAg negative paediatric patients, treatment should be administered until HBs<br />seroconversion or there is evidence of loss of efficacy.<br />Pharmacokinetics in paediatric patients with renal or hepatic impairment have not been<br />studied.<br />Elderly: no dosage adjustment based on age is required. The dose should be adjusted<br />according to the patient&#39;s renal function (see dosage recommendations in renal<br />impairment and section 5.2).<br />Gender and race: no dosage adjustment based on gender or race is required.<br />Renal impairment: the clearance of entecavir decreases with decreasing creatinine<br />clearance (see section 5.2). Dose adjustment is recommended for patients with<br />creatinine clearance &lt; 50 ml/min, including those on haemodialysis or continuous<br />ambulatory peritoneal dialysis (CAPD). A reduction of the daily dose using entecavir<br />oral solution, as detailed in the table, is recommended. As an alternative, in case the oral<br />solution is not available, the dose can be adjusted by increasing the dosage interval, also<br />shown in the table. The proposed dose modifications are based on extrapolation of<br />limited data, and their safety and effectiveness have not been clinically evaluated.<br />Therefore, virological response should be closely monitored.</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Hepavir dosage*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Nucleoside na&iuml;ve patients</strong></p></td><td style="vertical-align:top"><p><strong>Lamivudine-refractory or decompensated liver disease</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&ge;50</p></td><td style="vertical-align:top"><p>0.5 mg once daily</p></td><td style="vertical-align:top"><p>1 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>30 - 49</p></td><td style="vertical-align:top"><p>0.25 mg once daily*</p><p>OR</p><p>0.5 mg every 48 hours</p></td><td style="vertical-align:top"><p>0.5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>10 - 29</p></td><td style="vertical-align:top"><p>0.15 mg once daily*</p><p>OR</p><p>0.5 mg every 72 hours</p></td><td style="vertical-align:top"><p>0.3 mg once daily*</p><p>OR</p><p>0.5 mg every 48 hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10</p><p>&nbsp;</p><p>Haemodialysis or CAPD**</p></td><td style="vertical-align:top"><p>0.05 mg once daily*</p><p>OR</p><p>0.5 mg every 5-7 days</p></td><td style="vertical-align:top"><p>0.1 mg once daily*</p><p>OR</p><p>0.5 mg every 72 hours</p></td></tr></tbody></table><p>* for doses &lt; 0.5 mg Hepavir oral solution is recommended.<br />** on haemodialysis days, administer entecavir after haemodialysis.<br />Hepatic impairment: no dose adjustment is required in patients with hepatic<br />impairment.<br />Paediatric population: the safety and efficacy of Hepavir in children below 18 years of<br />age have not yet been established. No data are available.<br />Method of administration<br />Hepavir should be taken orally.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Renal impairment: dosage adjustment is recommended for patients with renal<br />impairment (see section 4.2). The proposed dose modifications are based on<br />extrapolation of limited data, and their safety and effectiveness have not been clinically<br />evaluated. Therefore, virological response should be closely monitored.<br />Exacerbations of hepatitis: spontaneous exacerbations in chronic hepatitis B are<br />relatively common and are characterised by transient increases in serum ALT. After<br />initiating antiviral therapy, serum ALT may increase in some patients as serum HBV<br />DNA levels decline (see section 4.8). Among entecavir-treated patients on-treatment<br />exacerbations had a median time of onset of 4-5 weeks. In patients with compensated<br />liver disease, these increases in serum ALT are generally not accompanied by an<br />increase in serum bilirubin concentrations or hepatic decompensation. Patients with<br />advanced liver disease or cirrhosis may be at a higher risk for hepatic decompensation<br />following hepatitis exacerbation, and therefore should be monitored closely during<br />therapy.<br />Acute exacerbation of hepatitis has also been reported in patients who have<br />discontinued hepatitis B therapy (see section 4.2). Post-treatment exacerbations are<br />usually associated with rising HBV DNA, and the majority appears to be self-limited.<br />However, severe exacerbations, including fatalities, have been reported.<br />Among entecavir-treated nucleoside naive patients, post-treatment exacerbations had a<br />median time to onset of 23-24 weeks, and most were reported in HBeAg negative<br />patients (see section 4.8). Hepatic function should be monitored at repeated intervals<br />with both clinical and laboratory follow-up for at least 6 months after discontinuation of<br />hepatitis B therapy. If appropriate, resumption of hepatitis B therapy may be warranted.<br />Patients with decompensated liver disease: a higher rate of serious hepatic adverse<br />events (regardless of causality) has been observed in patients with decompensated liver<br />disease, in particular in those with Child-Turcotte-Pugh (CTP) class C disease,<br />compared with rates in patients with compensated liver function. Also, patients with<br />decompensated liver disease may be at higher risk for lactic acidosis and for specific<br />renal adverse events such as hepatorenal syndrome. Therefore, clinical and laboratory<br />parameters should be closely monitored in this patient population (see also sections 4.8<br />and 5.1).<br />Lactic acidosis and severe hepatomegaly with steatosis: occurrences of lactic acidosis<br />(in the absence of hypoxaemia), sometimes fatal, usually associated with severe<br />hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside<br />analogues. As entecavir is a nucleoside analogue, this risk cannot be excluded.</p><p>Treatment with nucleoside analogues should be discontinued when rapidly elevating<br />aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis of<br />unknown aetiology occur. Benign digestive symptoms, such as nausea, vomiting and<br />abdominal pain, might be indicative of lactic acidosis development. Severe cases,<br />sometimes with fatal outcome, were associated with pancreatitis, liver failure/hepatic<br />steatosis, renal failure and higher levels of serum lactate. Caution should be exercised<br />when prescribing nucleoside analogues to any patient (particularly obese women) with<br />hepatomegaly, hepatitis or other known risk factors for liver disease. These patients<br />should be followed closely.<br />To differentiate between elevations in aminotransferases due to response to treatment<br />and increases potentially related to lactic acidosis, physicians should ensure that<br />changes in ALT are associated with improvements in other laboratory markers of<br />chronic hepatitis B.<br />Resistance and specific precaution for lamivudine-refractory patients: mutations in the<br />HBV polymerase that encode lamivudine-resistance substitutions may lead to the<br />subsequent emergence of secondary substitutions, including those associated with<br />entecavir associated resistance (ETVr). In a small percentage of lamivudine-refractory<br />patients, ETVr substitutions at residues rtT184, rtS202 or rtM250 were present at<br />baseline. Patients with lamivudine-resistant HBV are at higher risk of developing<br />subsequent entecavir resistance than patients without lamivudine resistance. The<br />cumulative probability of emerging genotypic entecavir resistance after 1, 2-, 3-, 4- and<br />5-years treatment in the lamivudine-refractory studies was 6%, 15%, 36%, 47% and<br />51%, respectively. Virological response should be frequently monitored in the<br />lamivudine-refractory population and appropriate resistance testing should be<br />performed. In patients with a suboptimal virological response after 24 weeks of<br />treatment with entecavir, a modification of treatment should be considered (see sections<br />4.5 and 5.1). When starting therapy in patients with a documented history of<br />lamivudine-resistant HBV, combination use of entecavir plus a second antiviral agent<br />(which does not share cross-resistance with either lamivudine or entecavir) should be<br />considered in preference to entecavir monotherapy.&nbsp;Pre-existing lamivudine-resistant HBV is associated with an increased risk for<br />subsequent entecavir resistance regardless of the degree of liver disease; in patients with<br />decompensated liver disease, virologic breakthrough may be associated with serious<br />clinical complications of the underlying liver disease. Therefore, in patients with both<br />decompensated liver disease and lamivudine-resistant HBV, combination use of<br />entecavir plus a second antiviral agent (which does not share cross-resistance with<br />either lamivudine or entecavir) should be considered in preference to entecavir<br />monotherapy.<br />Paediatric population: A lower rate of virologic response (HBV DNA &lt; 50 IU/ml) was<br />observed in paediatric patients with baseline HBV DNA &ge; 8.0 log10 IU/ml (see section<br />5.1). Entecavir should be used in these patients only if the potential benefit justifies the&nbsp;potential risk to the child (e.g. resistance). Since some paediatric patients may require<br />long-term or even lifetime management of chronic active hepatitis B, consideration<br />should be given to the impact of entecavir on future treatment options.<br />Liver transplant recipients: there are limited data on efficacy and safety of entecavir in<br />liver transplant recipients. Renal function should be carefully evaluated before and<br />during entecavir therapy in liver transplant recipients receiving cyclosporine or<br />tacrolimus (see section 5.2).<br />Co-infection with hepatitis C or D: there are no data on the efficacy of entecavir in<br />patients co-infected with hepatitis C or D virus.<br />Human immunodeficiency virus (HIV)/HBV co-infected patients not receiving<br />concomitant antiretroviral therapy: entecavir has not been evaluated in HIV/HBV coinfected<br />patients not concurrently receiving effective HIV treatment. Emergence of HIV<br />resistance has been observed when entecavir was used to treat chronic hepatitis B<br />infection in patients with HIV infection not receiving highly active antiretroviral<br />therapy (HAART) (see section 5.1). Therefore, therapy with entecavir should not be<br />used for HIV/HBV co-infected patients who are not receiving HAART. Entecavir has<br />not been studied as a treatment for HIV infection and is not recommended for this use.<br />HIV/HBV co-infected patients receiving concomitant antiretroviral therapy: entecavir<br />has been studied in 68 adults with HIV/HBV co-infection receiving a lamivudinecontaining<br />HAART regimen (see section 5.1). No data are available on the efficacy of<br />entecavir in HBeAg-negative patients co-infected with HIV. There are limited data on<br />patients co-infected with HIV who have low CD4 cell counts (&lt; 200 cells/mm3).<br />General: patients should be advised that therapy with entecavir has not been proven to<br />reduce the risk of transmission of HBV and therefore appropriate precautions should<br />still be taken.</p><p><strong>Tablets</strong><br />Lactose: this medicinal product contains 12.5 mg of lactose in each 0.5 mg daily dose.<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase<br />deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since entecavir is predominantly eliminated by the kidney (see section 5.2),<br />coadministration with medicinal products that reduce renal function or compete for<br />active tubular secretion may increase serum concentrations of either medicinal product.<br />Apart from lamivudine, adefovir dipivoxil and tenofovir disoproxil fumarate, the effects&nbsp;of coadministration of entecavir with medicinal products that are excreted renally or<br />affect renal function have not been evaluated. Patients should be monitored closely for<br />adverse reactions when entecavir is coadministered with such medicinal products.<br />No pharmacokinetic interactions between entecavir and lamivudine, adefovir or<br />tenofovir were observed.<br />Entecavir is not a substrate, an inducer or an inhibitor of cytochrome P450 (CYP450)<br />enzymes (see section 5.2). Therefore, CYP450 mediated drug interactions are unlikely<br />to occur with entecavir.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential: given that the potential risks to the developing foetus<br />are unknown, women of childbearing potential should use effective contraception.<br />Pregnancy: there are no adequate data from the use of entecavir in pregnant women.<br />Studies in animals have shown reproductive toxicity at high doses (see section 5.3). The<br />potential risk for humans is unknown. Hepavir should not be used during pregnancy<br />unless clearly necessary. There are no data on the effect of entecavir on transmission of<br />HBV from mother to newborn infant. Therefore, appropriate interventions should be<br />used to prevent neonatal acquisition of HBV.<br />Breastfeeding: it is unknown whether entecavir is excreted in human milk. Available<br />toxicological data in animals have shown excretion of entecavir in milk (for details see<br />section 5.3). A risk to the infants cannot be excluded. Breastfeeding should be<br />discontinued during treatment with Hepavir.<br />Fertility: toxicology studies in animals administered entecavir have shown no evidence<br />of impaired fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.<br />Dizziness, fatigue and somnolence are common side effects which may impair the<br />ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>a. Summary of the safety profile<br />In clinical studies in patients with compensated liver disease, the most common adverse&nbsp;reactions of any severity with at least a possible relation to entecavir were headache<br />(9%), fatigue (6%), dizziness (4%) and nausea (3%). Exacerbations of hepatitis during<br />and after discontinuation of entecavir therapy have also been reported (see section 4.4<br />and c. Description of selected adverse reactions).<br />b. Tabulated list of adverse reactions<br />Assessment of adverse reactions is based on experience from postmarketing<br />surveillance and four clinical studies in which 1,720 patients with chronic hepatitis B<br />infection and compensated liver disease received double-blind treatment with entecavir<br />(n = 862) or lamivudine (n = 858) for up to 107 weeks (see section 5.1). In these<br />studies, the safety profiles, including laboratory abnormalities, were comparable for<br />entecavir 0.5 mg daily (679 nucleoside-naive HBeAg positive or negative patients<br />treated for a median of 53 weeks), entecavir 1 mg daily (183 lamivudine-refractory<br />patients treated for a median of 69 weeks), and lamivudine.<br />Adverse reactions considered at least possibly related to treatment with entecavir are<br />listed by body system organ class. Frequency is defined as very common ( </em>&nbsp;&ge;&nbsp;<em>1/10);<br />common (</em>&nbsp;&ge;&nbsp;<em> 1/100 to &lt; 1/10); uncommon ( </em>&nbsp;&ge;&nbsp;<em>1/1,000 to &lt; 1/100); rare ( </em>&nbsp;&ge;&nbsp;<em>1/10,000 to &lt;<br />1/1,000). Within each frequency grouping, undesirable effects are presented in order of<br />decreasing seriousness.</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><em>Immune system disorders:</em></p></td><td style="vertical-align:top"><p>rare: anaphylactoid reaction</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders:</em></p></td><td style="vertical-align:top"><p>common: insomnia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders:</em></p></td><td style="vertical-align:top"><p>common: headache, dizziness, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders:</em></p></td><td style="vertical-align:top"><p>common: vomiting, diarrhoea, nausea, dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td><td style="vertical-align:top"><p>common: increased transaminases</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders:</em></p></td><td style="vertical-align:top"><p>uncommon: rash, alopecia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions:</em></p></td><td style="vertical-align:top"><p>common: fatigue</p></td></tr></tbody></table><p>Cases of lactic acidosis have been reported, often in association with hepatic<br />decompensation, other serious medical conditions or drug exposures (see section 4.4).<br />Treatment beyond 48 weeks: continued treatment with entecavir for a median duration<br />of 96 weeks did not reveal any new safety signals.<br /><em>c. Description of selected adverse reactions</em><br /><u>Laboratory test abnormalities:</u> In clinical studies with nucleoside-naive patients, 5% had<br />ALT elevations &gt; 3 times baseline, and &lt; 1% had ALT elevations &gt; 2 times baseline<br />together with total bilirubin &gt; 2 times upper limit of normal (ULN) and &gt; 2 times<br />baseline. Albumin levels &lt; 2.5 g/dl occurred in &lt; 1% of patients, amylase levels &gt; 3<br />times baseline in 2%, lipase levels &gt; 3 times baseline in 11% and platelets &lt;<br />50,000/mm3 in &lt; 1%.<br />In clinical studies with lamivudine-refractory patients, 4% had ALT elevations &gt; 3<br />times baseline, and &lt; 1% had ALT elevations &gt; 2 times baseline together with total<br />bilirubin &gt; 2 times ULN and &gt; 2 times baseline. Amylase levels &gt; 3 times baseline<br />occurred in 2% of patients, lipase levels &gt; 3 times baseline in 18% and platelets &lt;<br />50,000/mm3 in &lt; 1%.<br /><u>Exacerbations during treatment:</u> in studies with nucleoside naive patients, on treatment<br />ALT elevations &gt; 10 times ULN and &gt; 2 times baseline occurred in 2% of entecavir<br />treated patients vs 4% of lamivudine treated patients. In studies with lamivudinerefractory<br />patients, on treatment ALT elevations &gt; 10 times ULN and &gt; 2 times baseline<br />occurred in 2% of entecavir treated patients vs 11% of lamivudine treated patients.<br />Among entecavir-treated patients, on-treatment ALT elevations had a median time to<br />onset of 4-5 weeks, generally resolved with continued treatment, and, in a majority of<br />cases, were associated with a 2 log10/ml reduction in viral load that preceded or<br />coincided with the ALT elevation. Periodic monitoring of hepatic function is<br />recommended during treatment.</p><table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><u>.Exacerbations after discontinuation of treatment: </u>acute exacerbations of hepatitis have<br />been reported in patients who have discontinued anti-hepatitis B virus therapy,<br />including therapy with entecavir (see section 4.4). In studies in nucleoside-naive<br />patients, 6% of entecavir-treated patients and 10% of lamivudine-treated patients<br />experienced ALT elevations (&gt; 10 times ULN and &gt; 2 times reference [minimum of<br />baseline or last end-of-dosing measurement]) during post-treatment follow-up. Among<br />entecavir-treated nucleoside-naive patients, ALT elevations had a median time to onset<br />of 23-24 weeks, and 86% (24/28) of ALT elevations occurred in HBeAg negative<br />patients. In studies in lamivudine-refractory patients, with only limited numbers of<br />patients being followed up, 11% of entecavir-treated patients and no lamivudine-treated<br />patients developed ALT elevations during post-treatment follow-up.</p><p>In the clinical trials entecavir treatment was discontinued if patients achieved a<br />prespecified response. If treatment is discontinued without regard to treatment response,<br />the rate of post-treatment ALT flares could be higher.<br /><em>d. Paediatric Population</em><br />The safety of entecavir in paediatric patients from 2 to &lt; 18 years of age is based on two<br />clinical trials in subjects with chronic HBV infection; one Phase 2 pharmacokinetic trial<br />(study 028) and one Phase 3 trial (study 189). These trials provide experience in 195<br />HBeAg-positive nucleoside-treatment-na&iuml;ve subjects treated with entecavir for a<br />median duration of 99 weeks. The adverse reactions observed in paediatric subjects who<br />received treatment with entecavir were consistent with those observed in clinical trials<br />of entecavir in adults (see a. Summary of the safety profile and section 5.1) with the<br />following exception in the paediatric patients:</p><p>■ very common adverse reactions: neutropenia.<br /><em>e. Other special populations</em><br />Experience in patients with decompensated liver disease: the safety profile of entecavir<br />in patients with decompensated liver disease was assessed in a randomized open-label<br />comparative study in which patients received treatment with entecavir 1 mg/day (n =<br />102) or adefovir dipivoxil 10 mg/day (n = 89) (study 048). Relative to the adverse<br />reactions noted in section b. Tabulated list of adverse reactions, one additional adverse<br />reaction [decrease in blood bicarbonate (2%)] was observed in entecavir-treated patients<br />through week 48. The on-study cumulative death rate was 23% (23/102), and causes of<br />death were generally liver-related, as expected in this population. The on-study<br />cumulative rate of hepatocellular carcinoma (HCC) was 12% (12/102). Serious adverse<br />events were generally liver-related, with an on-study cumulative frequency of 69%.<br />Patients with high baseline CTP score were at higher risk of developing serious adverse<br />events (see section 4.4).<br />Laboratory test abnormalities: through week 48 among entecavir-treated patients with<br />decompensated liver disease, none had ALT elevations both &gt; 10 times ULN and &gt; 2<br />times baseline, and 1% of patients had ALT elevations &gt; 2 times baseline together with<br />total bilirubin &gt; 2 times ULN and &gt; 2 times baseline. Albumin levels &lt; 2.5 g/dl<br />occurred in 30% of patients, lipase levels &gt; 3 times baseline in 10% and platelets &lt;<br />50,000/mm3 in 20%.<br />Experience in patients co-infected with HIV: the safety profile of entecavir in a limited<br />number of HIV/HBV co-infected patients on lamivudine-containing HAART (highly<br />active antiretroviral therapy) regimens was similar to the safety profile in monoinfected<br />HBV patients (see section 4.4).</p><p>Gender/age: there was no apparent difference in the safety profile of entecavir with<br />respect to gender (&asymp; 25% women in the clinical trials) or age (&asymp; 5% of patients &gt; 65<br />years of age).</p><p><br /><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorization of the medicinal product is<br />important. It allows continued monitoring of the benefit/risk balance of the medicinal<br />product. Healthcare professionals are asked to report any suspected adverse reactions<br />via:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>To report any side effect(s):</p><p><br />For Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />SFDA Call Center: 19999.<br />E-mail:<u> npc.drug@sfda.gov.sa</u><br />Website:<u> https://ade.sfda.gov.sa</u><br />For UAE:<br />Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853<br />Tel: 80011111<br />Email: <u>pv@mohap.gov.ae</u><br />Drug Department<br />Ministry of Health &amp; Prevention,<br />Dubai<br />United Arab Emirates<br />For OMAN:<br />Department of Pharmacovigilance &amp; Drug Information<br />Directorate General of Pharmaceutical Affairs &amp; Drug Control<br />Ministry of Health, Sultanate of Oman<br />Phone Nos. 22357687 / 22357686<br />Fax: 22358489<br />Email: <u>dg-padc@moh.gov.om</u><br />Website: www.moh.gov.om</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited experience of entecavir overdose reported in patients. Healthy subjects<br />who received up to 20 mg/day for up to 14 days, and single doses up to 40 mg had no<br />unexpected adverse reactions. If overdose occurs, the patient must be monitored for<br />evidence of toxicity and given standard supportive treatment as necessary.</p><table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Pharmacotherapeutic group: antivirals for systemic use, nucleoside and nucleotide reverse<br />transcriptase inhibitors<br />ATC code: J05AF10<br />Mechanism of action: entecavir, a guanosine nucleoside analogue with activity against<br />HBV polymerase, is efficiently phosphorylated to the active triphosphate (TP) form,<br />which has an intracellular half-life of 15 hours. By competing with the natural substrate<br />deoxyguanosine TP, entecavir-TP functionally inhibits the 3 activities of the viral<br />polymerase: (1) priming of the HBV polymerase, (2) reverse transcription of the negative<br />strand DNA from the pregenomic messenger RNA, and (3) synthesis of the positive strand<br />HBV DNA. The entecavir-TP Ki for HBV DNA polymerase is 0.0012 &mu;M. Entecavir-TP<br />is a weak inhibitor of cellular DNA polymerases &alpha;, &beta;, and &delta; with Ki values of 18 to 40 &mu;M.<br />In addition, high exposures of entecavir had no relevant adverse effects on &gamma; polymerase<br />or mitochondrial DNA synthesis in HepG2 cells (Ki &gt; 160 &mu;M).<br />Antiviral activity: entecavir inhibited HBV DNA synthesis (50% reduction, EC50) at a<br />concentration of 0.004 &mu;M in human HepG2 cells transfected with wild-type HBV. The<br />median EC50 value for entecavir against LVDr HBV (rtL180M and rtM204V) was 0.026<br />&mu;M (range 0.010-0.059 &mu;M). Recombinant viruses encoding adefovir-resistant<br />substitutions at either rtN236T or rtA181V remained fully susceptible to entecavir.<br />An analysis of the inhibitory activity of entecavir against a panel of laboratory and clinical<br />HIV-1 isolates using a variety of cells and assay conditions yielded EC50 values ranging<br />from 0.026 to &gt; 10 &mu;M; the lower EC50 values were observed when decreased levels of<br />virus were used in the assay. In cell culture, entecavir selected for an M184I substitution<br />at micromolar concentrations, confirming inhibitory pressure at high entecavir<br />concentrations. HIV variants containing the M184V substitution showed loss of<br />susceptibility to entecavir (see section 4.4).<br />In HBV combination assays in cell culture, abacavir, didanosine, lamivudine, stavudine,<br />tenofovir or zidovudine were not antagonistic to the anti-HBV activity of entecavir over a<br />wide range of concentrations. In HIV antiviral assays, entecavir at micromolar&nbsp;concentrations was not antagonistic to the anti-HIV activity in cell culture of these six<br />NRTIs or emtricitabine.<br />Resistance in cell culture: relative to wild-type HBV, LVDr viruses containing rtM204V<br />and rtL180M substitutions within the reverse transcriptase exhibit 8-fold decreased<br />susceptibility to entecavir. Incorporation of additional ETVr amino acid changes rtT184,<br />rtS202 or rtM250 decreases entecavir susceptibility in cell culture. Substitutions observed<br />in clinical isolates (rtT184A, C, F, G, I, L, M or S; rtS202 C, G or I; and/or rtM250I, L or<br />V) further decreased entecavir susceptibility 16- to 741-fold relative to wild-type virus.<br />The ETVr substitutions at residues rtT184, rtS202 and rtM250 alone have only a modest<br />effect on entecavir susceptibility, and have not been observed in the absence of LVDr<br />substitutions in more than 1000 patient samples sequenced. Resistance is mediated by<br />reduced inhibitor binding to the altered HBV reverse transcriptase, and resistant HBV<br />exhibits reduced replication capacity in cell culture.<br />Clinical experience: the demonstration of benefit is based on histological, virological,<br />biochemical, and serological responses after 48 weeks of treatment in active-controlled<br />clinical trials of 1,633 adults with chronic hepatitis B infection, evidence of viral<br />replication and compensated liver disease. The safety and efficacy of entecavir were also<br />evaluated in an active-controlled clinical trial of 191 HBV-infected patients with<br />decompensated liver disease and in a clinical trial of 68 patients co-infected with HBV<br />and HIV.</p><p>In studies in patients with compensated liver disease, histological improvement was<br />defined as a &ge;&nbsp;2-point decrease in Knodell necro-inflammatory score from baseline with<br />no worsening of the Knodell fibrosis score. Responses for patients with baseline Knodell<br />Fibrosis Scores of 4 (cirrhosis) were comparable to overall responses on all efficacy<br />outcome measures (all patients had compensated liver disease). High baseline Knodell<br />necroinflammatory scores (&gt; 10) were associated with greater histological improvement in<br />nucleoside-naive patients. Baseline ALT levels &ge;&nbsp;2 times ULN and baseline HBV DNA<br />&ge;&nbsp;9.0 log10 copies/ml were both associated with higher rates of virologic response (Week<br />48 HBV DNA &lt; 400 copies/ml) in nucleoside-naive HBeAg-positive patients. Regardless<br />of baseline characteristics, the majority of patients showed histological and virological<br />responses to treatment.</p><p><u>Experience in nucleoside-naive patients with compensated liver disease:</u><br />Results at 48 weeks of randomised, double blind studies comparing entecavir (ETV) to<br />lamivudine (LVD) in HBeAg positive (022) and HBeAg negative (027) patients are<br />presented in the table.</p><table border="1" cellspacing="0" cellpadding="0" style="width:104%"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Nucleoside Naive</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>HBeAg Positive (study 022)</p></td><td colspan="2" style="vertical-align:top"><p>HBeAg Negative (study 027)</p></td></tr><tr><td style="vertical-align:top"><p>ETV 0.5 mg once daily</p></td><td style="vertical-align:top"><p>LVD 100 mg once daily</p></td><td style="vertical-align:top"><p>ETV 0.5 mg once daily</p></td><td style="vertical-align:top"><p>LVD 100 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>314<sup>a</sup></p></td><td style="vertical-align:top"><p>314<sup>a</sup></p></td><td style="vertical-align:top"><p>296<sup>a</sup></p></td><td style="vertical-align:top"><p>287<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Histological improvement<sup>b</sup></p></td><td style="vertical-align:top"><p>72%*</p></td><td style="vertical-align:top"><p>62%</p></td><td style="vertical-align:top"><p>70%*</p></td><td style="vertical-align:top"><p>61%</p></td></tr><tr><td style="vertical-align:top"><p>Ishak fibrosis score improvement</p></td><td style="vertical-align:top"><p>39%</p></td><td style="vertical-align:top"><p>35%</p></td><td style="vertical-align:top"><p>36%</p></td><td style="vertical-align:top"><p>38%</p></td></tr><tr><td style="vertical-align:top"><p>Ishak fibrosis score worsening</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>15%</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>354</p></td><td style="vertical-align:top"><p>355</p></td><td style="vertical-align:top"><p>325</p></td><td style="vertical-align:top"><p>313</p></td></tr><tr><td style="vertical-align:top"><p>Viral load reduction (log<sub>10</sub> copies/ml)<sup>c</sup></p></td><td style="vertical-align:top"><p>-6.86*</p></td><td style="vertical-align:top"><p>-5.39</p></td><td style="vertical-align:top"><p>-5.04*</p></td><td style="vertical-align:top"><p>-4.53</p></td></tr><tr><td style="vertical-align:top"><p>HBV DNA undetectable (&lt; 300 copies/ml by PCR)<sup>c</sup></p></td><td style="vertical-align:top"><p>67%*</p></td><td style="vertical-align:top"><p>36%</p></td><td style="vertical-align:top"><p>90%*</p></td><td style="vertical-align:top"><p>72%</p></td></tr><tr><td style="vertical-align:top"><p>ALT normalisation (<!--[if gte vml 1]><v:shape
     id="Picture_x0020_16" o:spid="_x0000_i1044" type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)"
     style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif"
      o:title="LESS-THAN OR EQUAL TO (8804)"/>
    </v:shape><![endif]-->&le; 1 times ULN)</p></td><td style="vertical-align:top"><p>68%*</p></td><td style="vertical-align:top"><p>60%</p></td><td style="vertical-align:top"><p>78%*</p></td><td style="vertical-align:top"><p>71%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HBeAg Seroconversion</p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>18%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*p value vs lamivudine &lt; 0.05</p><p><sup>a</sup> patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score <!--[if gte vml 1]><v:shape id="Picture_x0020_17"
     o:spid="_x0000_i1043" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
     style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
      o:title="GREATER-THAN OR EQUAL TO (8805)"/>
    </v:shape><![endif]-->&ge;2)</p><p><sup>b</sup> a primary endpoint</p><p><sup>c</sup> Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)</p></td></tr></tbody></table><p><strong><em><u>Experience in lamivudine-refractory patients with compensated liver disease:</u></em></strong><br /><em>In a randomised, double-blind study in HBeAg positive lamivudine-refractory patients<br />(026), with 85% of patients presenting LVDr mutations at baseline, patients receiving<br />lamivudine at study entry either switched to entecavir 1 mg once daily, with neither a<br />washout nor an overlap period (n = 141), or continued on lamivudine 100 mg once daily<br />(n = 145). Results at 48 weeks are presented in the table.</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Lamivudine-refractory</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>HBeAg positive (study 026)</p></td></tr><tr><td style="vertical-align:top"><p>ETV 1.0 mg once daily</p></td><td style="vertical-align:top"><p>LVD 100 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>124<sup>a</sup></p></td><td style="vertical-align:top"><p>116<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Histological improvement<sup>b</sup></p></td><td style="vertical-align:top"><p>55%*</p></td><td style="vertical-align:top"><p>28%</p></td></tr><tr><td style="vertical-align:top"><p>Ishak fibrosis score improvement</p></td><td style="vertical-align:top"><p>34%*</p></td><td style="vertical-align:top"><p>16%</p></td></tr><tr><td style="vertical-align:top"><p>Ishak fibrosis score worsening</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>26%</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>141</p></td><td style="vertical-align:top"><p>145</p></td></tr><tr><td style="vertical-align:top"><p>Viral load reduction (log<sub>10</sub> copies/ml)<sup>c</sup></p></td><td style="vertical-align:top"><p>-5.11*</p></td><td style="vertical-align:top"><p>-0.48</p></td></tr><tr><td style="vertical-align:top"><p>HBV DNA undetectable (&lt; 300 copies/ml by PCR)<sup>c</sup></p></td><td style="vertical-align:top"><p>19%*</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>ALT normalisation (<!--[if gte vml 1]><v:shape
     id="Picture_x0020_18" o:spid="_x0000_i1042" type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)"
     style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif"
      o:title="LESS-THAN OR EQUAL TO (8804)"/>
    </v:shape><![endif]-->&le; 1 times ULN)</p></td><td style="vertical-align:top"><p>61%*</p></td><td style="vertical-align:top"><p>15%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HBeAg Seroconversion</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*p value vs lamivudine &lt; 0.05</p><p><sup>a</sup> patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score <!--[if gte vml 1]><v:shape id="Picture_x0020_19"
     o:spid="_x0000_i1041" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
     style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
      o:title="GREATER-THAN OR EQUAL TO (8805)"/>
    </v:shape><![endif]-->&ge;2)</p><p><sup>b</sup> a primary endpoint.</p><p><sup>c</sup> Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)</p></td></tr></tbody></table><p><em><u>Results beyond 48 weeks of treatment:</u><br />Treatment was discontinued when prespecified response criteria were met either at 48<br />weeks or during the second year of treatment. Response criteria were HBV virological<br />suppression (HBV DNA &lt; 0.7 MEq/ml by bDNA) and loss of HBeAg (in HBeAg positive<br />patients) or ALT &lt; 1.25 times ULN (in HBeAg negative patients). Patients in response<br />were followed for an additional 24 weeks off-treatment. Patients who met virologic but<br />not serologic or biochemical response criteria continued blinded treatment. Patients who<br />did not have a virologic response were offered alternative treatment.</em></p><p><em>Nucleoside-naive:<br />HBeAg positive (study 022): treatment with entecavir for up to 96 weeks (n = 354)<br />resulted in cumulative response rates of 80% for HBV DNA &lt; 300 copies/ml by PCR,<br />87% for ALT normalisation, 31% for HBeAg seroconversion and 2% for HBsAg<br />seroconversion (5% for HBsAg loss). For lamivudine (n = 355), cumulative response rates<br />were 39% for HBV DNA &lt; 300 copies/ml by PCR, 79% for ALT normalisation, 26% for<br />HBeAg seroconversion, and 2% for HBsAg seroconversion (3% for HBsAg loss).<br />At end of dosing, among patients who continued treatment beyond 52 weeks (median of<br />96 weeks), 81% of 243 entecavir-treated and 39% of 164 lamivudine-treated patients had<br />HBV DNA &lt; 300 copies/ml by PCR while ALT normalisation ( 1 times ULN) occurred<br />in 79% of entecavir-treated and 68% of lamivudine-treated patients.<br />HBeAg negative (study 027): treatment with entecavir up to 96 weeks (n = 325) resulted<br />in cumulative response rates of 94% for HBV DNA &lt; 300 copies/ml by PCR and 89% for<br />ALT normalisation versus 77% for HBV DNA &lt; 300 copies/ml by PCR and 84% for ALT<br />normalisation for lamivudine-treated patients (n = 313).<br />For 26 entecavir-treated and 28 lamivudine-treated patients who continued treatment<br />beyond 52 weeks (median 96 weeks), 96% of entecavir-treated and 64% of lamivudinetreated<br />patients had HBV DNA &lt; 300 copies/ml by PCR at end of dosing. ALT<br />normalisation ( 1 times ULN) occurred in 27% of entecavir-treated and 21% of<br />lamivudine-treated patients at end of dosing.<br />For patients who met protocol-defined response criteria, response was sustained<br />throughout the 24-week post-treatment follow-up in 75% (83/111) of entecavir responders<br />vs 73% (68/93) for lamivudine responders in study 022 and 46% (131/286) of entecavir<br />responders vs 31% (79/253) for lamivudine responders in study 027. By 48 weeks of posttreatment<br />follow-up, a substantial number of HBeAg negative patients lost response.</em></p><p>Liver biopsy results: 57 patients from the pivotal nucleoside-naive studies 022 (HBeAg<br />positive) and 027 (HBeAg negative) who enrolled in a long-term rollover study were<br />evaluated for long-term liver histology outcomes. The entecavir dosage was 0.5 mg daily<br />in the pivotal studies (mean exposure 85 weeks) and 1 mg daily in the rollover study<br />(mean exposure 177 weeks), and 51 patients in the rollover study initially also received<br />lamivudine (median duration 29 weeks). Of these patients, 55/57 (96%) had histological<br />improvement as previously defined (see above), and 50/57 (88%) had a 1-point decrease<br />in Ishak fibrosis score. For patients with baseline Ishak fibrosis score 2, 25/43 (58%)<br />had a 2-point decrease. All (10/10) patients with advanced fibrosis or cirrhosis at<br />baseline (Ishak fibrosis score of 4, 5 or 6) had a 1 point decrease (median decrease from<br />baseline was 1.5 points). At the time of the long-term biopsy, all patients had HBV DNA<br />&lt; 300 copies/ml and 49/57 (86%) had serum ALT 1 times ULN. All 57 patients<br />remained positive for HBsAg.</p><p>Lamivudine-refractory:<br />HBeAg positive (study 026): treatment with entecavir for up to 96 weeks (n = 141)<br />resulted in cumulative response rates of 30% for HBV DNA &lt; 300 copies/ml by PCR,<br />85% for ALT normalisation and 17% for HBeAg seroconversion.<br />For the 77 patients who continued entecavir treatment beyond 52 weeks (median 96<br />weeks), 40% of patients had HBV DNA &lt; 300 copies/ml by PCR and 81% had ALT<br />normalisation (&le; 1 times ULN) at end of dosing.<br />Age/gender:</p><p>There was no apparent difference in efficacy for entecavir based on gender (&asymp; 25%<br />women in the clinical trials) or age (&asymp; 5% of patients &gt; 65 years of age).<br />Long-Term Follow-Up Study<br />Study 080 was a randomized, observational open-label Phase 4 study to assess long-term<br />risks of entecavir treatment (ETV, n=6,216) or other standard of care HBV nucleoside<br />(acid) treatment (non-ETV) (n=6,162) for up to 10 years in subjects with chronic HBV<br />(CHB) infection. The principal clinical outcome events assessed in the study were overall<br />malignant neoplasms (composite event of HCC and non-HCC malignant neoplasms), liver<br />related HBV disease progression, non-HCC malignant neoplasms, HCC, and deaths,<br />including liver related deaths. In this study, ETV was not associated with an increased risk<br />of malignant neoplasms compared to use of non-ETV, as assessed by either the composite<br />endpoint of overall malignant neoplasms (ETV n=331, non-ETV n=337; HR=0.93 [0.8-<br />1.1]), or the individual endpoint of non-HCC malignant neoplasm (ETV n=95, non-ETV<br />n=81; HR=1.1 [0.82-1.5]). The reported events for liver-related HBV disease progression<br />and HCC were comparable in both ETV and non-ETV groups. The most commonly<br />reported malignancy in both ETV and non-ETV groups was HCC followed by<br />gastrointestinal malignancies.</p><p><u>Special populations</u><br />Patients with decompensated liver disease: in study 048, 191 patients with HBeAg<br />positive or negative chronic HBV infection and evidence of hepatic decompensation,<br />defined as a CTP score of 7 or higher, received entecavir 1 mg once daily or adefovir<br />dipivoxil 10 mg once daily. Patients were either HBV-treatment-na&iuml;ve or pretreated<br />(excluding pretreatment with entecavir, adefovir dipivoxil, or tenofovir disoproxil<br />fumarate). At baseline, patients had a mean CTP score of 8.59 and 26% of patients were<br />CTP class C. The mean baseline Model for End Stage Liver Disease (MELD) score was<br />16.23. Mean serum HBV DNA by PCR was 7.83 log10 copies/ml and mean serum ALT<br />was 100 U/l; 54% of patients were HBeAg positive, and 35% of patients had LVDr<br />substitutions at baseline. Entecavir was superior to adefovir dipivoxil on the primary</p><p>efficacy endpoint of mean change from baseline in serum HBV DNA by PCR at week 24.<br />Results for selected study endpoints at weeks 24 and 48 are shown in the table.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Week 24</p></td><td colspan="2" style="vertical-align:top"><p>Week 48</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ETV</p><p>1 mg</p><p>once daily</p></td><td style="vertical-align:top"><p>Adefovir Dipivoxil</p><p>10 mg</p><p>once daily</p></td><td style="vertical-align:top"><p>ETV</p><p>1 mg</p><p>once daily</p></td><td style="vertical-align:top"><p>Adefovir Dipivoxil</p><p>10 mg</p><p>once daily</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>91</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>91</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>HBV DNA<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Proportion undetectable (&lt;300 copies/ml)<sup>b</sup></p></td><td style="vertical-align:top"><p>49%*</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>57%*</p></td><td style="vertical-align:top"><p>20%</p></td></tr><tr><td style="vertical-align:top"><p>Mean change from baseline (log<sub>10</sub> copies/ml)<sup>c</sup></p></td><td style="vertical-align:top"><p>-4.48*</p></td><td style="vertical-align:top"><p>-3.40</p></td><td style="vertical-align:top"><p>-4.66</p></td><td style="vertical-align:top"><p>-3.90</p></td></tr><tr><td style="vertical-align:top"><p>Stable or improved CTP score<sup>b,d</sup></p></td><td style="vertical-align:top"><p>66%</p></td><td style="vertical-align:top"><p>71%</p></td><td style="vertical-align:top"><p>61%</p></td><td style="vertical-align:top"><p>67%</p></td></tr><tr><td style="vertical-align:top"><p>MELD score</p><p>Mean change from baseline<sup>c,e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />-2.0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />-0.9</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />-2.6</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />-1.7</p></td></tr><tr><td style="vertical-align:top"><p>HBsAg loss<sup>b</sup></p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Normalization of:<sup>f</sup></p></td></tr><tr><td style="vertical-align:top"><p>ALT (&le;1 X ULN)<sup>b</sup></p></td><td style="vertical-align:top"><p>46/78 (59%)*</p></td><td style="vertical-align:top"><p>28/71 (39%)</p></td><td style="vertical-align:top"><p>49/78 (63%)*</p></td><td style="vertical-align:top"><p>33/71 (46%)</p></td></tr><tr><td style="vertical-align:top"><p>Albumin (&ge;1 X LLN)<sup>b</sup></p></td><td style="vertical-align:top"><p>20/82 (24%)</p></td><td style="vertical-align:top"><p>14/69 (20%)</p></td><td style="vertical-align:top"><p>32/82 (39%)</p></td><td style="vertical-align:top"><p>20/69 (29%)</p></td></tr><tr><td style="vertical-align:top"><p>Bilirubin (&le;1 X ULN)<sup>b</sup></p></td><td style="vertical-align:top"><p>12/75 (16%)</p></td><td style="vertical-align:top"><p>10/65 (15%)</p></td><td style="vertical-align:top"><p>15/75 (20%)</p></td><td style="vertical-align:top"><p>18/65 (28%)</p></td></tr><tr><td style="vertical-align:top"><p>Prothrombin time (&le;1 X ULN)<sup>b</sup></p></td><td style="vertical-align:top"><p>9/95 (9%)</p></td><td style="vertical-align:top"><p>6/82 (7%)</p></td><td style="vertical-align:top"><p>8/95 (8%)</p></td><td style="vertical-align:top"><p>7/82 (9%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a </sup>Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/ml).</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>b</sup> NC=F (noncompleter=failure), meaning treatment discontinuations before the analysis week, including reasons such as death, lack of efficacy, adverse event, noncompliance/loss-to-follow-up, are counted as failures (e.g., HBV DNA &ge;300 copies/ml)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>c</sup> NC=M (noncompleters=missing)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>d</sup> Defined as decrease or no change from baseline in CTP score.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>e </sup>Baseline mean MELD score was 17.1 for ETV and 15.3 for adefovir dipivoxil.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>f </sup>Denominator is patients with abnormal values at baseline.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*p&lt;0.05</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>ULN=upper limit of normal, LLN=lower limit of normal.</p></td></tr></tbody></table><p>The time to onset of HCC or death (whichever occurred first) was comparable in the two<br />treatment groups; on-study cumulative death rates were 23% (23/102) and 33% (29/89)<br />for patients treated with entecavir and adefovir dipivoxil, respectively, and on-study<br />cumulative rates of HCC were 12% (12/102) and 20% (18/89) for entecavir and adefovir<br />dipivoxil, respectively.<br />For patients with LVDr substitutions at baseline, the percentage of patients with HBV<br />DNA &lt;300 copies/ml was 44% for entecavir and 20% for adefovir at week 24 and 50%<br />for entecavir and 17% for adefovir at week 48.<br />HIV/HBV co-infected patients receiving concomitant HAART: study 038 included 67<br />HBeAg positive and 1 HBeAg negative patients co-infected with HIV. Patients had stable<br />controlled HIV (HIV RNA &lt; 400 copies/ml) with recurrence of HBV viraemia on a<br />lamivudine-containing HAART regimen. HAART regimens did not include emtricitabine<br />or tenofovir disoproxil fumarate. At baseline entecavir-treated patients had a median<br />duration of prior lamivudine therapy of 4.8 years and median CD4 count of 494 cells/mm3<br />(with only 5 subjects having CD4 count &lt; 200 cells/mm3). Patients continued their<br />lamivudine-regimen and were assigned to add either entecavir 1 mg once daily (n = 51) or<br />placebo (n = 17) for 24 weeks followed by an additional 24 weeks where all received<br />entecavir. At 24 weeks the reduction in HBV viral load was significantly greater with<br />entecavir (-3.65 vs an increase of 0.11 log10 copies/ml). For patients originally assigned to<br />entecavir treatment, the reduction in HBV DNA at 48 weeks was -4.20 log10 copies/ml,<br />ALT normalisation had occurred in 37% of patients with abnormal baseline ALT and<br />none achieved HBeAg seroconversion.<br />HIV/HBV co-infected patients not receiving concomitant HAART: entecavir has not been<br />evaluated in HIV/HBV co-infected patients not concurrently receiving effective HIV<br />treatment. Reductions in HIV RNA have been reported in HIV/HBV co-infected patients<br />receiving entecavir monotherapy without HAART. In some cases, selection of HIV<br />variant M184V has been observed, which has implications for the selection of HAART&nbsp;</p><p>regimens that the patient may take in the future. Therefore, entecavir should not be used in<br />this setting due to the potential for development of HIV resistance (see section 4.4).<br />Liver transplant recipients: the safety and efficacy of entecavir 1 mg once daily were<br />assessed in a single-arm study in 65 patients who received a liver transplant for<br />complications of chronic HBV infection and had HBV DNA &lt;172 IU/ml (approximately<br />1000 copies/ml) at the time of transplant. The study population was 82% male, 39%<br />Caucasian, and 37% Asian, with a mean age of 49 years; 89% of patients had HBeAgnegative<br />disease at the time of transplant. Of the 61 patients who were evaluable for<br />efficacy (received entecavir for at least 1 month), 60 also received hepatitis B immune<br />globulin (HBIg) as part of the post-transplant prophylaxis regimen. Of these 60 patients,<br />49 received more than 6 months of HBIg therapy. At Week 72 post-transplant, none of 55<br />observed cases had virologic recurrence of HBV [defined as HBV DNA &ge;50 IU/ml<br />(approximately 300 copies/ml)], and there was no reported virologic recurrence at time of<br />censoring for the remaining 6 patients. All 61 patients had HBsAg loss posttransplantation,<br />and 2 of these later became HBsAg positive despite maintaining<br />undetectable HBV DNA (&lt;6 IU/ml). The frequency and nature of adverse events in this<br />study were consistent with those expected in patients who have received a liver transplant<br />and the known safety profile of entecavir.</p><p>Paediatric population: Study 189 is a study of the efficacy and safety of entecavir among<br />180 nucleoside-treatment-na&iuml;ve children and adolescents from 2 to &lt; 18 years of age with<br />HBeAg-positive chronic hepatitis B infection, compensated liver disease, and elevated<br />ALT. Patients were randomized (2:1) to receive blinded treatment with entecavir 0.015<br />mg/kg up to 0.5 mg/day (N = 120) or placebo (N = 60). The randomization was stratified<br />by age group (2 to 6 years; &gt; 6 to 12 years; and &gt; 12 to &lt; 18 years). Baseline<br />demographics and HBV disease characteristics were comparable between the 2 treatment<br />arms and across age cohorts. At study entry, the mean HBV DNA was 8.1 log10 IU/ml and<br />mean ALT was 103 U/l across the study population. Results for the main efficacy<br />endpoints at Week 48 and Week 96 are presented in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:154px">&nbsp;</td><td rowspan="1" colspan="2" style="width:83px">Entecavir</td><td style="width:192px">Placebo*</td></tr><tr><td style="width:154px">&nbsp;</td><td style="width:83px">Week 48</td><td style="width:70px">Week 96</td><td style="width:192px">Week 48</td></tr><tr><td style="width:154px">n</td><td style="width:83px">120</td><td style="width:70px">120</td><td style="width:192px">60</td></tr><tr><td style="width:154px">HBV DNA &lt; 50 IU/mL and<br />HBeAg seroconversion a</td><td style="width:83px">24.2%</td><td style="width:70px">35.8%</td><td style="width:192px">3.3%</td></tr><tr><td style="width:154px">HBV DNA &lt; 50 IU/mL a</td><td style="width:83px">49.2%</td><td style="width:70px">64.2%</td><td style="width:192px">3.3.%</td></tr><tr><td style="width:154px">HBeAg seroconversion a</td><td style="width:83px">24.2%</td><td style="width:70px">36.7%</td><td style="width:192px">10.0%</td></tr><tr><td style="width:154px">ALT normalizationa</td><td style="width:83px">67.5%</td><td style="width:70px">81.7%</td><td style="width:192px">23.3%</td></tr><tr><td style="width:154px">HBV DNA &lt; 50 IU/mL a</td><td style="width:83px">&nbsp;</td><td style="width:70px">&nbsp;</td><td style="width:192px">&nbsp;</td></tr><tr><td style="width:154px">Baseline HBV<br />DNA &lt; 8 log10 IU/ml</td><td style="width:83px">82.6% (38/46)</td><td style="width:70px">82.6% (38/46)</td><td style="width:192px">6.5% (2/31)</td></tr><tr><td style="width:154px">Baseline HBV DNA<br />&ge; 8 log10 IU/ml</td><td style="width:83px">28.4% (21/74)</td><td style="width:70px">52.7% (39/74)</td><td style="width:192px">0% (0/29)</td></tr></tbody></table><p>a NC=F (noncompleter=failure)<br />* Patients randomized to placebo who did not have HBe- seroconversion by Week 48<br />rolled over to open-label entecavir for the second year of the study; therefore randomized<br />comparison data are available only through Week 48.<br />The paediatric resistance assessment is based on data from nucleoside-treatment-naive<br />paediatric patients with HBeAg-positive chronic HBV infection in two clinical trials (028<br />and 189). The two trials provide resistance data in 183 patients treated and monitored in<br />Year 1 and 180 patients treated and monitored in Year 2. Genotypic evaluations were<br />performed for all patients with available samples who had virologic breakthrough through<br />Week 96 or HBV DNA &ge; 50 IU/ml at Week 48 or Week 96 . During Year 2, genotypic<br />resistance to ETV was detected in 2 patients (1.1% cumulative probability of resistance<br />through Year 2).</p><p>&nbsp;</p><p>Clinical resistance in Adults: patients in clinical trials initially treated with entecavir 0.5<br />mg (nucleoside-naive) or 1.0 mg (lamivudine-refractory) and with an on-therapy PCR<br />HBV DNA measurement at or after Week 24 were monitored for resistance.<br />Through Week 240 in nucleoside-naive studies, genotypic evidence of ETVr substitutions<br />at rtT184, rtS202, or rtM250 was identified in 3 patients treated with entecavir, 2 of whom<br />experienced virologic breakthrough (see table). These substitutions were observed only in<br />the presence of LVDr substitutions (rtM204V and rtL180M).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="6" style="vertical-align:top"><p>Emerging Genotypic Entecavir Resistance Through Year 5, Nucleoside-Naive Studies</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Year 1</p></td><td style="vertical-align:top"><p>Year 2</p></td><td style="vertical-align:top"><p>Year 3<sup>a</sup></p></td><td style="vertical-align:top"><p>Year 4<sup>a</sup></p></td><td style="vertical-align:top"><p>Year 5<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Patients treated and monitored for resistance<sup>b</sup></p></td><td style="vertical-align:top"><p>663</p></td><td style="vertical-align:top"><p>278</p></td><td style="vertical-align:top"><p>149</p></td><td style="vertical-align:top"><p>121</p></td><td style="vertical-align:top"><p>108</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients in specific year with:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- emerging genotypic ETVr<sup>c</sup></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>- genotypic ETVr<sup>c</sup> with virologic breakthrough<sup>d</sup></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cumulative probability of:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- emerging genotypic ETVr<sup>c</sup></p></td><td style="vertical-align:top"><p>0.2%</p></td><td style="vertical-align:top"><p>0.5%</p></td><td style="vertical-align:top"><p>1.2%</p></td><td style="vertical-align:top"><p>1.2%</p></td><td style="vertical-align:top"><p>1.2%</p></td></tr><tr><td style="vertical-align:top"><p>- genotypic ETVr<sup>c</sup> with virologic breakthrough<sup>d</sup></p></td><td style="vertical-align:top"><p>0.2%</p></td><td style="vertical-align:top"><p>0.2%</p></td><td style="vertical-align:top"><p>0.8%</p></td><td style="vertical-align:top"><p>0.8%</p></td><td style="vertical-align:top"><p>0.8%</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a</sup> Results reflect use of a 1-mg dose of entecavir for 147 of 149 patients in Year 3 and all patients in Years 4 and 5 and of combination entecavir-lamivudine therapy (followed by long-term entecavir therapy) for a median of 20 weeks for 130 of 149 patients in Year 3 and for 1 week for 1 of 121 patients in Year 4 in a rollover study.</p><p><sup>b</sup> Includes patients with at least one on-therapy HBV DNA measurement by PCR at or after week 24 through week 58 (Year 1), after week 58 through week 102 (Year 2), after week 102 through week 156 (Year 3), after week 156 through week 204 (Year 4), or after week 204 through week 252 (Year 5).</p><p><sup>c</sup> Patients also have LVDr substitutions.</p><p><sup>d</sup><!--[if gte vml 1]><v:shape
     id="Picture_x0020_33" o:spid="_x0000_i1027" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
     style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
      o:title="GREATER-THAN OR EQUAL TO (8805)"/>
    </v:shape><![endif]-->&ge; 1 log<sub>10</sub> increase above nadir in HBV DNA by PCR, confirmed with successive measurements or at the end of the windowed time point.</p></td></tr></tbody></table><p>ETVr substitutions (in addition to LVDr substitutions rtM204V/I &plusmn; rtL180M) were<br />observed at baseline in isolates from 10/187 (5%) lamivudine-refractory patients treated<br />with entecavir and monitored for resistance, indicating that prior lamivudine treatment can<br />select these resistance substitutions and that they can exist at a low frequency before<br />entecavir treatment. Through Week 240, 3 of the 10 patients experienced virologic<br />breakthrough ( 1 log10 increase above nadir). Emerging entecavir resistance in<br />lamivudine-refractory studies through Week 240 is summarized in the table.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="6" style="vertical-align:top"><p>Genotypic Entecavir Resistance Through Year 5, Lamivudine-Refractory Studies</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Year 1</p></td><td style="vertical-align:top"><p>Year 2</p></td><td style="vertical-align:top"><p>Year 3<sup>a</sup></p></td><td style="vertical-align:top"><p>Year 4 <sup>a</sup></p></td><td style="vertical-align:top"><p>Year 5 <sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Patients treated and monitored for resistance<sup>b</sup></p></td><td style="vertical-align:top"><p>187</p></td><td style="vertical-align:top"><p>146</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients in specific year with:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- emerging genotypic ETVr<sup>c</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>- genotypic ETVr<sup>c</sup> with virologic breakthrough<sup>d</sup></p></td><td style="vertical-align:top"><p>2<sup>e</sup></p></td><td style="vertical-align:top"><p>14<sup>e</sup></p></td><td style="vertical-align:top"><p>13<sup>e</sup></p></td><td style="vertical-align:top"><p>9<sup>e</sup></p></td><td style="vertical-align:top"><p>1<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cumulative probability of:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- emerging genotypic ETVr<sup>c</sup></p></td><td style="vertical-align:top"><p>6.2%</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>36.3%</p></td><td style="vertical-align:top"><p>46.6%</p></td><td style="vertical-align:top"><p>51.45%</p></td></tr><tr><td style="vertical-align:top"><p>- genotypic ETVr<sup>c</sup> with virologic breakthrough<sup>d</sup></p></td><td style="vertical-align:top"><p>1.1%<sup>e</sup></p></td><td style="vertical-align:top"><p>10.7% <sup>e</sup></p></td><td style="vertical-align:top"><p>27% <sup>e</sup></p></td><td style="vertical-align:top"><p>41.3% <sup>e</sup></p></td><td style="vertical-align:top"><p>43.6% <sup>e</sup></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a</sup> Results reflect use of combination entecavir-lamivudine therapy (followed by long-term entecavir therapy) for a median of 13 weeks for 48 of 80 patients in Year 3, a median of 38 weeks for 10 of 52 patients in Year 4, and for 16 weeks for 1 of 33 patients in Year 5 in a rollover study.</p><p><sup>b</sup> Includes patients with at least one on-therapy HBV DNA measurement by PCR at or after week 24 through week 58 (Year 1), after week 58 through week 102 (Year 2), after week 102 through week 156 (Year 3), after week 156 through week 204 (Year 4), or after week 204 through week 252 (Year 5).</p><p><sup>c</sup> Patients also have LVDr substitutions.</p><p><sup>d</sup><!--[if gte vml 1]><v:shape
     id="Picture_x0020_35" o:spid="_x0000_i1025" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
     style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
      o:title="GREATER-THAN OR EQUAL TO (8805)"/>
    </v:shape><![endif]-->&ge; 1 log<sub>10</sub> increase above nadir in HBV DNA by PCR, confirmed with successive measurements or at the end of the windowed time point.</p><p><sup>e</sup> ETVr occurring in any year; virologic breakthrough in specified year.</p></td></tr></tbody></table><p>Among lamivudine-refractory patients with baseline HBV DNA &lt; 107 log10 copies/ml,<br />64% (9/14) achieved HBV DNA &lt; 300 copies/ml at Week 48. These 14 patients had a<br />lower rate of genotypic entecavir resistance (cumulative probability 18.8% through 5<br />years of follow-up) than the overall study population (see table). Also, lamivudinerefractory<br />patients who achieved HBV DNA &lt; 104 log10 copies/ml by PCR at Week 24<br />had a lower rate of resistance than those who did not (5-year cumulative probability<br />17.6% [n= 50] versus 60.5% [n= 135], respectively).<br />Integrated Analysis of Phase 2 and 3 Clinical Studies: In a post-approval integrated<br />analysis of entecavir resistance data from 17 Phase 2 and 3 clinical studies, an emergent<br />entecavir resistance-associated substitution rtA181C was detected in 5 out of 1461<br />subjects during treatment with entecavir. This substitution was detected only in the&nbsp;presence of lamivudine resistance-associated substitutions rtL180M plus rtM204V.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption: entecavir is rapidly absorbed with peak plasma concentrations occurring<br />between 0.5-1.5 hours. The absolute bioavailability has not been determined. Based on<br />urinary excretion of unchanged drug, the bioavailability has been estimated to be at least<br />70%. There is a dose-proportionate increase in Cmax and AUC values following multiple<br />doses ranging from 0.1-1 mg. Steady-state is achieved between 6-10 days after once daily<br />dosing with &asymp; 2 times accumulation. Cmax and Cmin at steady-state are 4.2 and 0.3 ng/ml,<br />respectively, for a dose of 0.5 mg, and 8.2 and 0.5 ng/ml, respectively, for 1 mg.<br />Administration of 0.5 mg entecavir with a standard high-fat meal (945 kcal, 54.6 g fat) or a<br />light meal (379 kcal, 8.2 g fat) resulted in a minimal delay in absorption (1-1.5 hour fed vs.<br />0.75 hour fasted), a decrease in Cmax of 44-46%, and a decrease in AUC of 18-20%. The<br />lower Cmax and AUC when taken with food is not considered to be of clinical relevance in<br />nucleoside-naive patients but could affect efficacy in lamivudine-refractory patients (see<br />section 4.2).<br />Distribution: the estimated volume of distribution for entecavir is in excess of total body<br />water. Protein binding to human serum protein in vitro is &asymp; 13%.<br />Biotransformation: entecavir is not a substrate, inhibitor or inducer of the CYP450 enzyme<br />system. Following administration of 14C-entecavir, no oxidative or acetylated metabolites<br />and minor amounts of the phase II metabolites, glucuronide and sulfate conjugates, were<br />observed.<br />Elimination: entecavir is predominantly eliminated by the kidney with urinary recovery of<br />unchanged drug at steady-state of about 75% of the dose. Renal clearance is independent<br />of dose and ranges between 360-471 ml/min suggesting that entecavir undergoes both<br />glomerular filtration and net tubular secretion. After reaching peak levels, entecavir<br />plasma concentrations decreased in a bi-exponential manner with a terminal elimination<br />half-life of &asymp; 128-149 hours. The observed drug accumulation index is &asymp; 2 times with once<br />daily dosing, suggesting an effective accumulation half-life of about 24 hours.<br />Hepatic impairment: pharmacokinetic parameters in patients with moderate or severe<br />hepatic impairment were similar to those in patients with normal hepatic function.<br />Renal impairment: entecavir clearance decreases with decreasing creatinine clearance. A 4<br />hour period of haemodialysis removed &asymp; 13% of the dose, and 0.3% was removed by<br />CAPD. The pharmacokinetics of entecavir following a single 1 mg dose in patients<br />(without chronic hepatitis B infection) are shown in the table below:</p><table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Baseline Creatinine Clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unimpaired</strong></p><p>&gt; 80</p><p>(n = 6)</p></td><td style="vertical-align:top"><p><strong>Mild</strong></p><p>&gt; 50; <!--[if gte vml 1]><v:shapetype id="_x0000_t75"
     coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
     filled="f" stroked="f">
     <v:stroke joinstyle="miter"/>
     <v:formulas>
      <v:f eqn="if lineDrawn pixelLineWidth 0"/>
      <v:f eqn="sum @0 1 0"/>
      <v:f eqn="sum 0 0 @1"/>
      <v:f eqn="prod @2 1 2"/>
      <v:f eqn="prod @3 21600 pixelWidth"/>
      <v:f eqn="prod @3 21600 pixelHeight"/>
      <v:f eqn="sum @0 0 1"/>
      <v:f eqn="prod @6 1 2"/>
      <v:f eqn="prod @7 21600 pixelWidth"/>
      <v:f eqn="sum @8 21600 0"/>
      <v:f eqn="prod @7 21600 pixelHeight"/>
      <v:f eqn="sum @10 21600 0"/>
     </v:formulas>
     <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
     <o:lock v:ext="edit" aspectratio="t"/>
    </v:shapetype><v:shape id="Picture_x0020_36" o:spid="_x0000_i1025" type="#_x0000_t75"
     alt="LESS-THAN OR EQUAL TO (8804)" style='width:9pt;height:9pt;
     visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
      o:title="LESS-THAN OR EQUAL TO (8804)"/>
    </v:shape><![endif]-->&le;80</p><p>(n = 6)</p></td><td style="vertical-align:top"><p><strong>Moderate</strong></p><p>30-50</p><p>(n = 6)</p></td><td style="vertical-align:top"><p><strong>Severe</strong></p><p>20-&lt; 30</p><p>(n = 6)</p></td><td style="vertical-align:top"><p><strong>Severe Managed with Haemodialysis</strong></p><p><br /><br /><br /><br /><br /><br />(n = 6)</p></td><td style="vertical-align:top"><p><strong>Severe Managed with CAPD</strong></p><p><br /><br /><br /><br /><br /><br />(n = 4)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (ng/ml)</p><p>(CV%)</p></td><td style="vertical-align:top"><p>8.1</p><p>(30.7)</p></td><td style="vertical-align:top"><p>10.4</p><p>(37.2)</p></td><td style="vertical-align:top"><p>10.5</p><p>(22.7)</p></td><td style="vertical-align:top"><p>15.3</p><p>(33.8)</p></td><td style="vertical-align:top"><p>15.4</p><p>(56.4)</p></td><td style="vertical-align:top"><p>16.6</p><p>(29.7)</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>(0-T)</sub> (ng&middot;h /ml)</p><p>(CV)</p></td><td style="vertical-align:top"><p>27.9</p><p>(25.6)</p></td><td style="vertical-align:top"><p>51.5</p><p>(22.8)</p></td><td style="vertical-align:top"><p>69.5</p><p>(22.7)</p></td><td style="vertical-align:top"><p>145.7</p><p>(31.5)</p></td><td style="vertical-align:top"><p>233.9</p><p>(28.4)</p></td><td style="vertical-align:top"><p>221.8</p><p>(11.6)</p></td></tr><tr><td style="vertical-align:top"><p>CLR (ml/min)</p><p>(SD)</p></td><td style="vertical-align:top"><p>383.2</p><p>(101.8)</p></td><td style="vertical-align:top"><p>197.9</p><p>(78.1)</p></td><td style="vertical-align:top"><p>135.6</p><p>(31.6)</p></td><td style="vertical-align:top"><p>40.3</p><p>(10.1)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>CLT/F (ml/min)</p><p>(SD)</p></td><td style="vertical-align:top"><p>588.1</p><p>(153.7)</p></td><td style="vertical-align:top"><p>309.2</p><p>(62.6)</p></td><td style="vertical-align:top"><p>226.3</p><p>(60.1)</p></td><td style="vertical-align:top"><p>100.6</p><p>(29.1)</p></td><td style="vertical-align:top"><p>50.6</p><p>(16.5)</p></td><td style="vertical-align:top"><p>35.7</p><p>(19.6)</p></td></tr></tbody></table><p><em>Post-Liver transplant: entecavir exposure in HBV-infected liver transplant recipients on a<br />stable dose of cyclosporine A or tacrolimus (n = 9) was &asymp; 2 times the exposure in healthy<br />subjects with normal renal function. Altered renal function contributed to the increase in<br />entecavir exposure in these patients (see section 4.4).<br />Gender: AUC was 14% higher in women than in men, due to differences in renal function<br />and weight. After adjusting for differences in creatinine clearance and body weight there<br />was no difference in exposure between male and female subjects.<br />Elderly: the effect of age on the pharmacokinetics of entecavir was evaluated comparing&nbsp;elderly subjects in the age range 65-83 years (mean age females 69 years, males 74 years)<br />with young subjects in the age range 20-40 years (mean age females 29 years, males 25<br />years). AUC was 29% higher in elderly than in young subjects, mainly due to differences<br />in renal function and weight. After adjusting for differences in creatinine clearance and<br />body weight, elderly subjects had a 12.5% higher AUC than young subjects.The<br />population pharmacokinetic analysis covering patients in the age range 16-75 years did not<br />identify age as significantly influencing entecavir pharmacokinetics.<br />Race: the population pharmacokinetic analysis did not identify race as significantly<br />influencing entecavir pharmacokinetics. However, conclusions can only be drawn for the<br />Caucasian and Asian groups as there were too few subjects in the other categories.<br />Paediatric population: the steady-state pharmacokinetics of entecavir were evaluated<br />(study 028) in 24 nucleoside na&iuml;ve HBeAg-positive paediatric subjects from 2 to &lt; 18<br />years of age with compensated liver disease. Entecavir exposure among nucleoside na&iuml;ve<br />subjects receiving once daily doses of entecavir 0.015 mg/kg up to a maximum dose of 0.5<br />mg was similar to the exposure achieved in adults receiving once daily doses of 0.5 mg.<br />The Cmax, AUC(0-24), and Cmin for these subjects was 6.31 ng/ml, 18.33 ng h/ml, and<br />0.28 ng/ml, respectively.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>In repeat-dose toxicology studies in dogs, reversible perivascular inflammation was<br />observed in the central nervous system, for which no-effect doses corresponded to<br />exposures 19 and 10 times those in humans (at 0.5 and 1 mg respectively). This finding<br />was not observed in repeat-dose studies in other species, including monkeys<br />administered entecavir daily for 1 year at exposures <!--[if gte vml 1]><v:shape
 id="Picture_x0020_40" o:spid="_x0000_i1026" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="GREATER-THAN OR EQUAL TO (8805)"/>
</v:shape><![endif]-->&ge;&nbsp; 100 times those in humans.<br />In reproductive toxicology studies in which animals were administered entecavir for up<br />to 4 weeks, no evidence of impaired fertility was seen in male or female rats at high<br />exposures. Testicular changes (seminiferous tubular degeneration) were evident in<br />repeat-dose toxicology studies in rodents and dogs at exposures <!--[if gte vml 1]><v:shape
 id="Picture_x0020_40" o:spid="_x0000_i1026" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="GREATER-THAN OR EQUAL TO (8805)"/>
</v:shape><![endif]-->&ge; 26 times those in<br />humans. No testicular changes were evident in a 1-year study in monkeys.<br />In pregnant rats and rabbits administered entecavir, no effect levels for embryotoxicity<br />and maternal toxicity corresponded to exposures&nbsp; <!--[if gte vml 1]><v:shape
 id="Picture_x0020_40" o:spid="_x0000_i1026" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="GREATER-THAN OR EQUAL TO (8805)"/>
</v:shape><![endif]-->&ge;&nbsp; 21 times those in humans. In rats,<br />maternal toxicity, embryo-foetal toxicity (resorptions), lower foetal body weights, tail<br />and vertebral malformations, reduced ossification (vertebrae, sternebrae, and<br />phalanges), and extra lumbar vertebrae and ribs were observed at high exposures. In<br />rabbits, embryo-foetal toxicity (resorptions), reduced ossification (hyoid), and an<br />increased incidence of 13th rib were observed at high exposures. In a peri-postnatal<br />study in rats, no adverse effects on offspring were observed. In a separate study wherein<br />entecavir was administered to pregnant lactating rats at 10 mg/kg, both foetal exposure<br />to entecavir and secretion of entecavir into milk were demonstrated. In juvenile rats&nbsp;administered entecavir from postnatal days 4 to 80, a moderately reduced acoustic<br />startle response was noted during the recovery period (postnatal days 110 to 114) but<br />not during the dosing period at AUC values &ge; 92 times those in humans at the 0.5 mg<br />dose or paediatric equivalent dose. Given the exposure margin, this finding is<br />considered of unlikely clinical significance.<br />No evidence of genotoxicity was observed in an Ames microbial mutagenicity assay, a<br />mammalian-cell gene mutation assay, and a transformation assay with Syrian hamster<br />embryo cells. A micronucleus study and a DNA repair study in rats were also negative.<br />Entecavir was clastogenic to human lymphocyte cultures at concentrations substantially<br />higher than those achieved clinically.<br />Two-year carcinogenicity studies: in male mice, increases in the incidences of lung<br />tumours were observed at exposures <!--[if gte vml 1]><v:shape
 id="Picture_x0020_40" o:spid="_x0000_i1026" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="GREATER-THAN OR EQUAL TO (8805)"/>
</v:shape><![endif]-->&ge;&nbsp; 4 and <!--[if gte vml 1]><v:shape
 id="Picture_x0020_40" o:spid="_x0000_i1026" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="GREATER-THAN OR EQUAL TO (8805)"/>
</v:shape><![endif]-->&ge;&nbsp; 2 times that in humans at 0.5 mg and 1<br />mg respectively. Tumour development was preceded by pneumocyte proliferation in the<br />lung which was not observed in rats, dogs, or monkeys, indicating that a key event in<br />lung tumour development observed in mice likely was species-specific. Increased<br />incidences of other tumours including brain gliomas in male and female rats, liver<br />carcinomas in male mice, benign vascular tumours in female mice, and liver adenomas<br />and carcinomas in female rats were seen only at high lifetime exposures. However, the<br />no effect levels could not be precisely established. The predictivity of the findings for<br />humans is not known. For clinical data, see section 5.1.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose BP 200<br />Avicel pH 102<br />Crosvidone NF<br />Povidone K-30<br />Magnesium Stearate<br /><strong>Film-Coating Materials</strong><br />Opadry Pink YS-1-1472 S<br />Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Not applicable.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months/ 3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30/pack<br />OPA/AL/PVC Reel and Aluminium Foil.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>No Special Disposal.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>